The purpose of this study was to assess the impact of body mass index (BMI) and diabetes mellitus (DM) on angiographic outcomes in patients treated with different drug-eluting stents. Methods: From November 2002 to March 2011, 8567 de novo coronary lesions were treated with drug-eluting stent. Dialysis patients were excluded. Of 8567 lesions, 1934 lesions were treated with everolimus-eluting stent (EES), 1215 with paclitaxel-eluting stent (PES), and 5418 with sirolimus-eluting stent (SES). Angiographic follow-up was routinely performed at 8 months after successful procedure. The follow-up rate was 81%. The patients were classified as underweight (BMI Ͼ20), normal weight (BMI Ն20 and Ͼ25), and overweight (BMI Ն25). The patients were divided into three groups according to implanted stent type: EES, PES, and SES. Of all patients, 42% were with DM, of whom 11% were insulin-dependent. The rates of DM and insulin treatment were similar in all groups. Angiographic outcomes were compared between each group. Results: Independent predictors of binary restenosis differed in each group. In the SES group, they were BMI (depression of 5 kg/m2), DM, bifurcation, chronic total obstruction (CTO), stent size 2.5 mm, and lesion length Ն20 mm. In the PES group, they were BMI (depression of 5 kg/m2), DM, and stent size 2.5 mm. In the EES group, they were CTO, stent size 2.5 mm, and lesion length Ն20 mm. The figure shows odds ratio of BMI (depression of 5 kg/m2) and DM between each group.
TCT-346 Clinical Impact of Five-month Follow-up Glycosylated Hemoglobin on Cardiovascular Outcomes in Diabetic Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background: Diabetes mellitus is known as a strong predictive factor of adverse cardiovascular event after ST-segment elevation myocardial infarction (STEMI). Recently, glycosylated hemoglobin (HbA1c) reflecting serum glucose control within 8 to 12 weeks, is studied to investigate relationship with major adverse cardiac events (MACE) after acute myocardial infarction. This study is conducted to determine the association between follow-up HbA1c and MACE in diabetic patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Methods: Using data from Korea Working Group on Myocardial Infarction, 303 diabetic patients with STEMI undergoing primary PCI were enrolled. Patients were divided into three groups based on follow-up HbA1c(FU-HbA1c): optimal, FU-HbA1c Ͼ7%; suboptimal, 7%ՅFU-HbA1cϾ9%, poor controlled group, 9%ՅFU-HbA1c. We analyzed 12-month cumulative MACE, defined as a composite of mortality, nonfatal myocardial infarction, re-PCI or coronary artery bypass graft in each group. Also, we investigated the value of FU-HbA1c to predict MACE using multivariate logistic regression analysis. Results: The mean duration of HbA1c and clinical event follow-up was 5 and 12 months, respectively. The incidence rate of 12-month cumulative MACE were significantly different in each group: 7.3% vs 13.0% vs 23.9%, respectively (pϭ0.005), which was mainly due to increased repeated PCI. In multivariate logistic analysis, the factor of FU-HbA1c more than 9.0% was shown to be independently associated with 12-month cumulative MACE, and compared with FU-HbA1cϾ7.0%: OR 11.437, 95% confidence interval 1.709-76.522, pϭ0.012. Conclusions: This study suggests that FU-HbA1c in early phase was associated with higher incidence of 12-month cumulative MACE, mainly contributing to increased repeated PCI in diabetic patients with STEMI undergoing primary PCI. And more than 9% of FU-HbA1c was identified to be an independent predictor of adverse outcome. These imply continuous tight monitoring of serum glucose in early phase after myocardial ischemic insult is important to reduce the possibility of repeated PCI following restenosis, but more research is needed to understand these findings with long-term clinical data. 
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